TerminatedNCT00369915
The Antidepressant Efficacy of the Anticholinergic Scopolamine
This study assesses depression symptoms.
Medication studyAges 18–55United States
Understand this study
What is this study about?
This study assesses depression symptoms.
Who could participate?
Listed age limits: 18 years to 55 years.
- Listed locations
- BethesdaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateAugust 2006
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 17
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00369915
- Official title
Show the full official title
The Antidepressant Efficacy of the Anticholinergic Scopolamine
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bethesda
Interested in joining this study?
Questions about this study
What is this study about?
This study assesses depression symptoms.
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Does this study involve medication?
Yes. The study involves medication, including Scopolamine.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as terminated.
